BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24682281)

  • 1. Strong epistatic interactions within a single protein.
    Parera M; Martinez MA
    Mol Biol Evol; 2014 Jun; 31(6):1546-53. PubMed ID: 24682281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
    Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
    Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
    Mello IM; Thumann C; Schvoerer E; Soulier E; Pinho JR; Silvestre DA; Queiroz AT; Wolf P; Baumert TF; Keller FS; Pereira CA
    J Viral Hepat; 2009 Oct; 16(10):732-7. PubMed ID: 19486468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Imhof I; Simmonds P
    Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease.
    Yang SH; Lee CG; Song MK; Sung YC
    Virology; 2000 Mar; 268(1):132-40. PubMed ID: 10683335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epistasis as a determinant of the HIV-1 protease's robustness to mutation.
    Capel E; Parera M; Martinez MA
    PLoS One; 2014; 9(12):e116301. PubMed ID: 25551558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S; Clotet B; Martínez MA
    Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C NS3 protease: restoration of NS4A cofactor activity by N-biotinylation of mutated NS4A using synthetic peptides.
    Butkiewicz NJ; Yao N; Wright-Minogue J; Zhang R; Ramanathan L; Lau JY; Hong Z; Dasmahapatra B
    Biochem Biophys Res Commun; 2000 Jan; 267(1):278-82. PubMed ID: 10623610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical point mutations for hepatitis C virus NS3 proteinase.
    Yamada K; Mori A; Seki M; Kimura J; Yuasa S; Matsuura Y; Miyamura T
    Virology; 1998 Jun; 246(1):104-12. PubMed ID: 9656998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic survey of an intragenic epistatic landscape.
    Bank C; Hietpas RT; Jensen JD; Bolon DN
    Mol Biol Evol; 2015 Jan; 32(1):229-38. PubMed ID: 25371431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
    Failla CM; Pizzi E; De Francesco R; Tramontano A
    Fold Des; 1996; 1(1):35-42. PubMed ID: 9079362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
    Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate specificity of the NS3 serine proteinase of hepatitis C virus as determined by mutagenesis at the NS3/NS4A junction.
    Leinbach SS; Bhat RA; Xia SM; Hum WT; Stauffer B; Davis AR; Hung PP; Mizutani S
    Virology; 1994 Oct; 204(1):163-9. PubMed ID: 8091650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper.
    Welker MW; Susser S; Welsch C; Perner D; Füller C; Kronenberger B; Herrmann E; Zeuzem S; Sarrazin C
    J Viral Hepat; 2012 Nov; 19(11):775-83. PubMed ID: 23043384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.
    Beyer BM; Zhang R; Hong Z; Madison V; Malcolm BA
    Proteins; 2001 May; 43(2):82-8. PubMed ID: 11276078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
    Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
    Geitmann M; Dahl G; Danielson UH
    J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.